Libentech

Libentech is a South Korean biotechnology company specializing in the development of next-generation gene therapies for rare genetic disorders. The company leverages its proprietary adeno-associated virus (AAV) vector platform to create highly efficient and safe treatments, with a primary focus on lysosomal storage diseases. Their lead programs, LBT-101 and LBT-102, target Pompe disease and Fabry disease respectively, aiming to provide long-term therapeutic benefits through a single administration. Libentech is dedicated to overcoming the limitations of current enzyme replacement therapies by utilizing advanced genetic engineering techniques to improve vector delivery and expression.